Abbott Laboratories (ABTT34) Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
ABTT34 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.26 |
| 52 Week High | US$67.65 |
| 52 Week Low | US$49.00 |
| Beta | 0.70 |
| 1 Month Change | -6.99% |
| 3 Month Change | -7.34% |
| 1 Year Change | -2.64% |
| 3 Year Change | 30.06% |
| 5 Year Change | 11.93% |
| Change since IPO | 397.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABTT34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -2.8% | -2.3% | 1.8% |
| 1Y | -2.6% | 0.7% | 5.5% |
Return vs Industry: ABTT34 underperformed the BR Medical Equipment industry which returned 0.8% over the past year.
Return vs Market: ABTT34 underperformed the BR Market which returned 6.9% over the past year.
Price Volatility
| ABTT34 volatility | |
|---|---|
| ABTT34 Average Weekly Movement | 3.1% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BR Market | 8.5% |
| 10% least volatile stocks in BR Market | 2.0% |
Stable Share Price: ABTT34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: ABTT34's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABTT34 fundamental statistics | |
|---|---|
| Market cap | R$1.16t |
| Earnings (TTM) | R$74.92b |
| Revenue (TTM) | R$235.87b |
Is ABTT34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABTT34 income statement (TTM) | |
|---|---|
| Revenue | US$43.84b |
| Cost of Revenue | US$19.18b |
| Gross Profit | US$24.67b |
| Other Expenses | US$10.74b |
| Earnings | US$13.93b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.01 |
| Gross Margin | 56.26% |
| Net Profit Margin | 31.76% |
| Debt/Equity Ratio | 25.3% |
How did ABTT34 perform over the long term?
See historical performance and comparisonDividends
Does ABTT34 pay a reliable dividends?
See ABTT34 dividend history and benchmarks| Abbott Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Oct 14 2025 |
| Dividend Pay Date | Nov 24 2025 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 20 days |
Does ABTT34 pay a reliable dividends?
See ABTT34 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 19:59 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbott Laboratories is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |